


## PHARMACEUTICAL 2022



## Travere Therapeutics Inc. Rank 310 of 466





## PHARMACEUTICAL 2022



## Travere Therapeutics Inc. Rank 310 of 466

The relative strengths and weaknesses of Travere Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Travere Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 32% points. The greatest weakness of Travere Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 84% points.

The company's Economic Capital Ratio, given in the ranking table, is 54%, being 24% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	582,827
Cost of Goods Sold	6,784
Intangible Assets	148,435
Liabilities, Current	124,088
Liabilities, Non-Current	64,152
Other Assets	34,265
Other Compr. Net Income	340
Other Expenses	22,669
Other Liabilities	286,281
Other Net Income	-17,917
Other Revenues	227,490
Property and Equipment	11,106
Research and Development	210,328
Selling, General and Administrative Expense	149,883

Output Variable	Value in 1000 USD
Assets	776,633
Liabilities	474,521
Expenses	389,664
Revenues	227,490
Stockholders Equity	302,112
Net Income	-180,091
Comprehensive Net Income	-179,921
Economic Capital Ratio	54%

